Janus Henderson Group PLC Acquires 268,250 Shares of Silence Therapeutics plc (NASDAQ:SLN)

Janus Henderson Group PLC raised its position in shares of Silence Therapeutics plc (NASDAQ:SLN - Free Report) by 32.8% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,087,228 shares of the company's stock after purchasing an additional 268,250 shares during the quarter. Janus Henderson Group PLC owned 3.63% of Silence Therapeutics worth $19,798,000 at the end of the most recent quarter.

A number of other hedge funds also recently modified their holdings of the business. Values First Advisors Inc. acquired a new stake in shares of Silence Therapeutics during the third quarter worth approximately $56,000. Quarry LP acquired a new stake in shares of Silence Therapeutics during the 2nd quarter valued at $114,000. Marshall Wace LLP grew its holdings in shares of Silence Therapeutics by 7.3% during the 2nd quarter. Marshall Wace LLP now owns 149,397 shares of the company's stock valued at $2,839,000 after acquiring an additional 10,206 shares in the last quarter. Verition Fund Management LLC acquired a new position in shares of Silence Therapeutics in the third quarter worth $207,000. Finally, Custom Index Systems LLC purchased a new stake in shares of Silence Therapeutics during the second quarter worth $282,000. Hedge funds and other institutional investors own 98.73% of the company's stock.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on SLN. Jefferies Financial Group started coverage on Silence Therapeutics in a research note on Tuesday, September 3rd. They issued a "buy" rating and a $40.00 target price on the stock. HC Wainwright reissued a "buy" rating and issued a $75.00 price target on shares of Silence Therapeutics in a research note on Friday, November 15th. Chardan Capital reaffirmed a "buy" rating and set a $55.00 price objective on shares of Silence Therapeutics in a research report on Thursday, November 14th. William Blair reissued an "outperform" rating on shares of Silence Therapeutics in a research report on Tuesday, November 19th. Finally, BMO Capital Markets restated an "outperform" rating on shares of Silence Therapeutics in a report on Monday, December 2nd. Six analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has an average rating of "Buy" and a consensus target price of $57.20.

Silence Therapeutics Price Performance

SLN traded up $0.37 on Friday, hitting $8.52. The company had a trading volume of 517,529 shares, compared to its average volume of 864,451. The stock has a market cap of $255.00 million, a price-to-earnings ratio of -5.43 and a beta of 1.05. The company's fifty day moving average price is $14.84 and its 200 day moving average price is $17.60. Silence Therapeutics plc has a 1-year low of $5.81 and a 1-year high of $27.72.

Silence Therapeutics Company Profile

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.